Quarterly ResultAug 6, 2026, 06:02 AM
Prestige Consumer Raises FY27 Outlook on Acquisitions; Q1 Revenue $265.7M
AI Summary
Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, with revenue up 6.5% to $265.7 million and organic sales growth of 3.2%, exceeding expectations. The company also announced the completion of the Breathe Right® and LaCorium acquisitions. Consequently, Prestige Consumer Healthcare raised its fiscal 2027 outlook for revenue, Adjusted Diluted EPS, and Adjusted Free Cash Flow, reflecting the positive impact of these strategic acquisitions and robust business performance.
Key Highlights
- Q1 Revenue increased 6.5% to $265.7 million; organic sales grew 3.2%.
- Q1 Adjusted Diluted EPS was $0.98, up from $0.95 in the prior year.
- Q1 Adjusted Non-GAAP Free Cash Flow reached $83.7 million, up from $78.2 million.
- Closed Breathe Right® and LaCorium acquisitions in June and July, respectively.
- Raised fiscal 2027 revenue outlook to $1,290-$1,315 million.
- Raised fiscal 2027 Adjusted Diluted EPS outlook to $4.55-$4.65.
- Raised fiscal 2027 Adjusted Free Cash Flow outlook to $270 million or more.
- North American OTC Healthcare segment revenue grew 6.4% to $226.2 million.
Price Impact
More from PBH